Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 7/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.39 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28438631 | 1.00 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3KDM4ETSHR | |
| Bromide SCHEMBL10566997 | 0.98 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3KDM4ETSHR | |
| SCHEMBL30910020 | 0.83 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3KDM4ETSHR | |
| SCHEMBL30663811 | 0.81 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3KDM4ETSHR | |
| SCHEMBL7268370 | 0.81 | KCNA5 (0.52) | SLC6A2SLC6A4SLC6A3KDM4ETSHR | |
| SCHEMBL6481541 | 0.81 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3KDM4ETSHR | |
| SCHEMBL506917 | 0.81 | KCNA5 (0.52) | SLC6A2SLC6A4SLC6A3KDM4ETSHR | |
| SCHEMBL29767197 | 0.81 | KCNA5 (0.52) | SLC6A2SLC6A4SLC6A3KDM4ETSHR | |
| SCHEMBL31744336 | 0.81 | KCNA5 (0.52) | SLC6A2SLC6A4SLC6A3KDM4ETSHR | |
| SCHEMBL211788 | 0.81 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111499639-B | Pyrimidone derivatives and their use in pharmacy | 四川大学华西医院 | 2022-03-04 | — | — | CN | disclosed |
| CN-111499639-A | Pyrimidone derivatives and their use in pharmacy | 四川大学华西医院 | 2020-08-07 | — | — | CN | disclosed |
| US-8993773-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2015-03-31 | — | — | US | disclosed |
| US-20140088127-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | CADILA HEALTHCARE LIMITED (IN) | 2014-03-27 | — | — | US | disclosed |
| US-8445685-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2013-05-21 | — | — | US | disclosed |
| US-8173816-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2012-05-08 | — | — | US | disclosed |
| US-20120077848-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | CADILA HEALTHCARE LIMITED (IN) | 2012-03-29 | — | — | US | disclosed |
| US-20110021576-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | CADILA HEALTHCARE LIMITED (IN) | 2011-01-27 | — | — | US | disclosed |
| US-7863300-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2011-01-04 | — | — | US | disclosed |
| US-7671207-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2010-03-02 | — | — | US | disclosed |
| US-7465801-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2008-12-16 | — | — | US | disclosed |
| US-20080300282-A1 | Novel process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2008-12-04 | — | — | US | disclosed |
| US-20080004446-A1 | Novel process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2008-01-03 | — | — | US | disclosed |
| EP-1521753-B1 | A PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL INTERMEDIATES. | CADILA HEALTHCARE LTD (IN) | 2007-09-05 | — | — | EP | disclosed |
| US-4005212-A | ANTIDEPRESSANT, ANOREXIGENIC, PSYCHOENERGIZING, 2-PHENYL-2,3,5,6-TETRAHYDROIMIDAZO(2,1-B)THIAZOLE | RHONE-POULENC S.A. (FR) | 1977-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004446-A1 | Novel process to prepare pioglitazone via several novel intermediates | PPARD, PPARG, PPARA | SLC6A2 3596/4885SLC6A4 1946/4885SLC6A3 2240/4885 |
| US-20140088127-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | PPARD, PPARG, PPARA | SLC6A2 3856/4885SLC6A4 2260/4885SLC6A3 2730/4885 |
| US-20080300282-A1 | Novel process to prepare pioglitazone via several novel intermediates | PPARD, PPARG, PPARA | SLC6A2 3856/4885SLC6A4 2260/4885SLC6A3 2730/4885 |
| US-20120077848-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | PPARD, PPARG, PPARA | SLC6A2 3856/4885SLC6A4 2260/4885SLC6A3 2730/4885 |
| US-20110021576-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | PPARD, PPARG, PPARA | SLC6A2 3856/4885SLC6A4 2260/4885SLC6A3 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.